Effect of High Velocity/Hyperoxic Breathing Therapy on Blood Lactate Decline

HVT has been found to be a useful clinical tool for treatment of Type 1 and Type 2 respiratory failure (including hypercapnic respiratory failure), acute decompensated heart failure, and COVID respiratory complications. The overall objective of this prospective, pilot study is to evaluate whether HVT might enhance the decline of blood lactate concentrations following a high intensity exercise bout, in healthy volunteers. The hypothesis is that HVT, regardless of the oxygen concentration (i.e., FiO2), will reduce the work of breathing and increase the lactate clearance rate during exercise and recovery intervals. This pilot study could ignite further research providing HVT applications to high performing athletics and patients in an acute care setting requiring physical rehabilitation.

Inclusion criteria

• Adults18-30 years old, in a general state of good health, of either sex
• No known contraindication to performing a maximal exercise test, i.e., Wingate-type Anaerobic exercise test
• Participants must consider themselves able to perform "regular moderate" or "regular strenuous" exercise.
• ° "Regular moderate" exercise includes less than 30 minutes every day or 30 minutes every other day, of some form of deliberate exercise, that does not include walking.
• ° "Regular strenuous" exercise is 30+ minutes per day, of some form of deliberate exercise, that does not include walking.

Exclusion criteria

• Not considered a 'high-performance athlete'
• Known active cardiovascular, metabolic, liver, or renal disease
• Orthopedic limitations to exercise
• Pregnancy
• Use of beta-blockers or beta-agonist asthma medications
• Exercise induced asthma
• Any other health-related issue that would involve the participant's fitness capability
• Inability to complete all of the study procedures